tbResList Print — MushReishi Mushroom Reishi

Filters: qv=235, qv2=%, rfv=%

Product

MushReishi Mushroom Reishi
Description: <b>Reishi mushroom (Ganoderma lucidum)</b><br>
-Various compounds such as glycoproteins, polysaccharides, triterpenoids, meroterpenoids, sesquiterpenoids, steroids, alkaloids, benzopyran derivatives, and benzoic acid derivatives, and minerals such as potassium, calcium, phosphorus, magnesium, selenium, iron and zinc.<br>
-Most important polysaccharides and triterpenes. <br>
-Polysaccharides, especially beta-glucans (ability to support immune system function) <br>
<br>
Higher bioavailability in liquid form<br>
<br>
Pathways<br>
-Enhances activity of natural killer (NK) cells, dendritic cells, and T lymphocytes
-NF-κB Inhibition<br>



<p><b>Mushroom Reishi</b> — Reishi is a medicinal polypore mushroom historically described as <i>Ganoderma lucidum</i> and also known as Lingzhi; modern taxonomy indicates that much East Asian medicinal material historically reported as <i>G. lucidum</i> is more accurately assigned to <i>Ganoderma sichuanense</i> or closely related <i>Ganoderma</i> species. It is classified as a food-source medicinal mushroom rather than a single pharmacologically defined compound. Standard names include Reishi, Lingzhi, <i>G. lucidum</i>, and GL; the Nestronics abbreviation is MushReishi. Its principal bioactive fractions are high-molecular-weight polysaccharides, particularly β-glucans, and lanostane-type triterpenoids including ganoderic and ganoderenic acids. These fractions have substantially different pharmacology: polysaccharides are principally immunomodulatory, whereas triterpenoids and some whole-mushroom extracts produce direct antiproliferative effects in experimental cancer models. Extract composition varies substantially with species, fruiting body versus mycelium, growth substrate, extraction method, and standardization.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Immune modulation by β-glucan-rich polysaccharides, including activation or enhancement of macrophage, dendritic-cell, NK-cell and T-cell functions through pattern-recognition pathways including Dectin-1 and complement-associated signaling.</li>
<li>Induction of cancer-cell apoptosis and growth arrest by triterpenoids and concentrated extracts, involving mitochondrial caspase signaling, death-receptor pathways, p53 signaling and cell-cycle regulatory proteins.</li>
<li>Suppression of PI3K/AKT/mTOR, IGF receptor, MAPK/ERK, NF-κB and related proliferative and survival signaling in multiple preclinical cancer models.</li>
<li>ROS-mediated cancer-cell injury and programmed cell death, including caspase-3/GSDME-associated pyroptosis in some models; NRF2 suppression has been observed in colorectal cancer cells but is a secondary, model-dependent mechanism.</li>
<li>Reduction of tumor-cell migration, invasion and angiogenic signaling, including modulation of VEGF, MMP-related pathways, ERK and translation-associated signaling.</li>
<li>Chemosensitization through inhibition of ABCB1/P-glycoprotein-mediated drug efflux by selected triterpenoids and extracts, increasing intracellular exposure to agents such as doxorubicin and paclitaxel in resistant experimental models.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> Reishi is not a single chemical entity, so systemic exposure depends strongly on the preparation. High-molecular-weight β-glucans are poorly absorbed intact from the gastrointestinal tract and their biological effects are predominantly mediated through gastrointestinal and immune interfaces rather than high circulating concentrations. Ganoderic acids can undergo gastrointestinal absorption, hepatic phase-I and phase-II metabolism, biliary elimination and interconversion, but quantitative PK evidence is predominantly animal-based. Human pharmacokinetic data sufficient to connect oral supplement doses with anticancer concentrations remain limited. Claims that liquid Reishi preparations are intrinsically more bioavailable than other standardized extracts are not established as a general property.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Direct cancer-cell studies commonly use concentrated extracts in the tens to hundreds of µg/mL range or isolated triterpenoids at micromolar concentrations. These exposures cannot presently be assumed to be achievable in human tumors after ordinary oral Reishi supplementation. Direct cytotoxic mechanisms should therefore be regarded primarily as preclinical. Immune effects may occur at lower or indirect exposures and have human evidence, but demonstration of immune modulation does not establish an anticancer survival benefit.</p>

<p><b>Clinical evidence status:</b> Preclinical evidence is extensive, with small human studies and limited randomized evidence for immune modulation and supportive outcomes. Cancer-specific clinical studies have generally evaluated immune biomarkers, quality of life or adjunct use rather than robust tumor-response or survival endpoints. Current evidence does not establish Reishi as a stand-alone cancer treatment. In the United States medicinal mushroom products are marketed as dietary supplements and Reishi is not FDA-approved for treatment of cancer or any other medical condition. Human safety is generally acceptable in trials, but rare hepatotoxicity reports exist and supplement composition is variable.</p>


<h3>Reishi Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>β-Glucan Immune Signaling</td>
<td>Indirect antitumor pressure ↑</td>
<td>NK cells ↑; T cells ↑; dendritic-cell and macrophage activity ↑</td>
<td>Immune activation</td>
<td>Most biologically plausible systemic mechanism for polysaccharide-rich preparations. Receptor-level mechanisms are best established for fungal β-glucans generally; product-specific activity varies.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial Apoptosis</td>
<td>Caspase-9 ↑; caspase-3 ↑; apoptosis ↑</td>
<td>Generally lower cytotoxicity at moderate concentrations (model-dependent)</td>
<td>Programmed cell death</td>
<td>Observed with purified triterpenoids, spore oil and whole extracts in several tumor models.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K AKT mTOR Signaling</td>
<td>PI3K ↓; AKT ↓; mTORC1/2 ↓</td>
<td>Context-dependent</td>
<td>Growth and survival suppression</td>
<td>Reported in breast, lung and esophageal cancer models; often accompanied by reduced protein synthesis and proliferation.</td>
</tr>
<tr>
<td>4</td>
<td>Cell Cycle Regulation</td>
<td>CDK4 ↓; E2F1 ↓; p21 ↑; G0/G1 arrest ↑</td>
<td>Less characterized</td>
<td>Proliferation arrest</td>
<td>Strongly dependent on the triterpenoid or extract composition and cancer model.</td>
</tr>
<tr>
<td>5</td>
<td>NF-κB and MAPK Signaling</td>
<td>NF-κB ↓; ERK signaling ↓</td>
<td>Inflammatory NF-κB signaling ↓ (context-dependent)</td>
<td>Reduced survival, inflammation and invasion signaling</td>
<td>NF-κB inhibition occurs in both cancer cells and activated immune cells and therefore is not intrinsically cancer-selective.</td>
</tr>
<tr>
<td>6</td>
<td>Mitochondrial ROS Increase</td>
<td>ROS ↑; oxidative DNA injury ↑; cell death ↑</td>
<td>↔ to ↑ toxicity at high concentration</td>
<td>Oxidative stress-mediated cytotoxicity</td>
<td>Secondary and preparation-dependent. Some studies report preferential tumor-cell toxicity relative to peripheral lymphocytes.</td>
</tr>
<tr>
<td>7</td>
<td>NRF2 Redox Defense</td>
<td>NRF2 ↓ (model-dependent)</td>
<td>Insufficient evidence</td>
<td>Reduced oxidative-stress tolerance</td>
<td>Observed in colorectal cancer cells and should not be generalized to all Reishi preparations or tumor types.</td>
</tr>
<tr>
<td>8</td>
<td>Migration and Invasion</td>
<td>Migration ↓; invasion ↓; metastatic behavior ↓</td>
<td>Not established</td>
<td>Antimetastatic activity</td>
<td>Associated with inhibition of PI3K/AKT/mTOR, ERK, NF-κB and downstream invasion-associated proteins.</td>
</tr>
<tr>
<td>9</td>
<td>Angiogenic Signaling</td>
<td>VEGF-related signaling ↓</td>
<td>Not established</td>
<td>Reduced angiogenic signaling</td>
<td>Predominantly preclinical evidence.</td>
</tr>
<tr>
<td>10</td>
<td>ABCB1 Drug Efflux and Chemosensitization</td>
<td>P-glycoprotein transport ↓; intracellular chemotherapy exposure ↑; Chemosensitization ↑</td>
<td>Drug-interaction relevance possible</td>
<td>Reversal of multidrug resistance</td>
<td>Demonstrated for ganoderenic acid B, ganoderiol F and some Reishi extracts. Evidence remains preclinical and may imply pharmacologic interaction risk.</td>
</tr>
<tr>
<td>11</td>
<td>Caspase 3 GSDME Pyroptosis</td>
<td>Caspase-3 ↑; GSDME cleavage ↑; pyroptosis ↑</td>
<td>Not established</td>
<td>Inflammatory tumor-cell death</td>
<td>Reported in breast cancer models; not established as a general Reishi mechanism.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Direct cytotoxic exposure uncertain</td>
<td>Systemic immune effects more plausible</td>
<td>Limits extrapolation to human cancer</td>
<td>Major constraints include heterogeneous species and extracts, variable β-glucan and triterpenoid content, limited human PK, predominantly preclinical direct-cytotoxicity data, and lack of convincing cancer survival trials.</td>
</tr>
</tbody>
</table>


Pathway results for Effect on Cancer / Diseased Cells

Immune & Inflammatory Signaling(tgid=16) ⓘ

CR3↝, 1,   NK cell↑, 1,   T-Cell↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 2,   Dose↑, 1,   eff↑, 1,  

Functional Outcomes(tgid=23) ⓘ

QoL↑, 1,   Remission↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag
2015A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green TeaDawn Lemanne, Keith I. Block—https://pmc.ncbi.nlm.nih.gov/articles/PMC4739749/pdf/cureus-0007-000000000441.pdf0
2016Ganoderma lucidum (Reishi mushroom) for cancer treatmentXingzhong JinPMC6353236https://pmc.ncbi.nlm.nih.gov/articles/PMC6353236/0